Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group.
Tilley B, Alarcón G, Heyse S, Trentham D, Neuner R, Kaplan D, Clegg D, Leisen J, Buckley L, Cooper S, Duncan H, Pillemer S, Tuttleman M, Fowler S. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Annals Of Internal Medicine 1995, 122: 81-9. PMID: 7993000, DOI: 10.7326/0003-4819-122-2-199501150-00001.Peer-Reviewed Original ResearchConceptsIgM rheumatoid factor levelsErythrocyte sedimentation rateRheumatoid factor levelsRheumatoid arthritisMinocycline groupGlobal assessmentPlacebo groupMore patientsPlatelet countModified Health Assessment QuestionnaireFactor levelsEfficacy of minocyclineEvaluator's global assessmentWeek 48 visitActive rheumatoid arthritisHealth Assessment QuestionnairePatient global assessmentPlacebo-controlled trialModerate rheumatoid arthritisDisease-modifying drugsMechanism of actionJoint tendernessMorning stiffnessStudy medicationDisease activity